Adjuvant Systemic Chemotherapy With or Without HAI-FUDR in Patients With Resected CRLM

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE3

Total Enrollment

92 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-05-28

Study Completion Date

2021-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

HARVEST is an investigator-initiated prospective randomized controlled study comparing adjuvant intravenous systemic chemotherapy with or without HAI- floxuridine (FUDR) in CRC patients post-liver metastasectomy.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

FUDR/Oxaliplatin HAI Plus Irinotecan vs. FOLFOXIRI Chemotherapy in Treating Initially Unresectable CRCLM

NCT03678428

Metastatic Colorectal Cancer Liver Metastases

TERMINATED PHASE3

A Study of Systemic Chemotherapy With CPT-11 Plus HAI (FUDR+L-OHP) in Patients With Initially Unresectable CRCLM

NCT03493061

Colo-rectal Cancer Liver Metastases

COMPLETED PHASE2

Pre- and Post-operative FOLFOX Based Therapy for Patients With Colorectal Cancer With Liver Involvement

NCT00537823

Colorectal Cancer Metastases

TERMINATED PHASE2

Hepatic Arterial Infusion Chemotherapy Combined With Sintilimab and Regorafenib as Adjuvant Therapy for Colorectal Liver Metastasis Patients With a High Risk of Recurrent: a Single-arm, Phase II Study

NCT05753163

Colorectal Liver Metastasis

UNKNOWN PHASE2

FOLFOX Via HAI Plus Intravenous Irinotecan With or Without Bevacizumab Versus Systemic FOLFOXIRI With or Without Bevacizumab in Initially Unresectable RAS-mutated CRLM Patients

NCT05727163

Colorectal Cancer Metastatic

RECRUITING PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Numerous retrospective studies have indicated a positive synergistic effect of combining adjuvant oxaliplatin/irinotecan-based doublet systemic chemotherapy and hepatic arterial infusion (HAI) for colorectal cancer (CRC) patients following colorectal cancer liver metastases (CRLM) resection. However, this strategy has not been evaluated prospectively to date. HARVEST is an investigator-initiated prospective randomized controlled study comparing adjuvant intravenous systemic chemotherapy with or without HAI- floxuridine (FUDR) in CRC patients post-liver metastasectomy.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Colorectal Cancer Liver Metastases HAI

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

HAI group

Patients will receive systemic chemotherapy on days 1 and 15 using either of the following regimens: mFOLFOX6 (Oxaliplatin 85 mg/m2; Leucovorin 200mg/m2; followed by an infusion of 5-fluorouracil 2.4 g/m2 administered over 46 hours) or mFOLFIRI (Irinotecan 180mg/m2; Leucovorin 200mg/m2; followed by an infusion of 5-fluorouracil 2.4 g/m2 administered over 46 hours) For HAI, FUDR was administered as a continuous infusion of 0.12 mg/kg/day over 14 days via the HAI pump, along with dexamethasone 20 mg, and normal saline was used to fill up the 300ml pump reservoir.

Group Type EXPERIMENTAL

FUDR

Intervention Type DRUG

Floxuridine(FUDR) 0.12 mg/kg/day，on Day 1-14 through the HAI pump.

Oxaliplatin

Intervention Type DRUG

Oxaliplatin 180 mg/m2 IV over 90 minutes on Day 1, 15.

Leucovorin

Intervention Type DRUG

Leucovorin 200mg/m2 ivd over 2 hours on Day 1

5FU

Intervention Type DRUG

5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion on Day 1.

Irinotecan

Intervention Type DRUG

Irinotecan 180mg/m2

Non-HAI group

Patients will receive systemic chemotherapy on days 1 and 15 using either of the following regimens: mFOLFOX6 (oxalipatin 85 mg/m2 infusion for 3 h, Leucovorin 200 mg/m2 for 3 h and 5-FU 2,400 mg/m2 continuous infusion for 46 h) or mFOLFIRI (Irinotecan 180mg/m2; Leucovorin 200mg/m2; 5-FU 2,400 mg/m2 continuous infusion for 46 h).

Group Type ACTIVE_COMPARATOR

Oxaliplatin

Intervention Type DRUG

Oxaliplatin 180 mg/m2 IV over 90 minutes on Day 1, 15.

Leucovorin

Intervention Type DRUG

Leucovorin 200mg/m2 ivd over 2 hours on Day 1

5FU

Intervention Type DRUG

5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion on Day 1.

Irinotecan

Intervention Type DRUG

Irinotecan 180mg/m2

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

FUDR

Floxuridine(FUDR) 0.12 mg/kg/day，on Day 1-14 through the HAI pump.

Intervention Type DRUG

Oxaliplatin

Oxaliplatin 180 mg/m2 IV over 90 minutes on Day 1, 15.

Intervention Type DRUG

Leucovorin

Leucovorin 200mg/m2 ivd over 2 hours on Day 1

Intervention Type DRUG

5FU

5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion on Day 1.

Intervention Type DRUG

Irinotecan

Irinotecan 180mg/m2

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Floxuridine Xaliplatin Folinic Acid 5-Fluorouracil CPT-11

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. The primary lesion has undergone or is capable of radical resection, and liver metastases can undergo R0/R1 resection (including intraoperative interventional ablation therapy), and postoperative achievement of no evidence of disease (NED).
2. Histologically confirmed colorectal adenocarcinoma
3. Radiologically or pathologically confirmed diagnosis of colorectal liver metastasis
4. No previous surgery, interventional ablation, hepatic arterial infusion (HAI), radiotherapy, or transarterial chemoembolization (TACE) for liver metastases.
5. CT, MRI, or PET/CT (if necessary) confirmed no extrahepatic metastasis.
6. Normal hematologic function (platelets \> 90×10\^9/L; white blood cells \> 3×10\^9/L; neutrophils \> 1.5×10\^9/L).
7. No ascites, normal coagulation function, albumin ≥ 35g/L.
8. Liver function graded as Child-Pugh class A.
9. Serum bilirubin ≤ 1.5 times the upper limit of normal (ULN), transaminases ≤ 5 times ULN, alkaline phosphatase ≤ 2.5 ULN.
10. Serum creatinine below the upper limit of normal (ULN), or calculated creatinine clearance \> 50ml/min (using Cockcroft-Gault formula).
11. ECOG performance status of 0-2
12. Life expectancy ≥ 3 months
13. Patients have provided a signed Informed Consent Form
14. Willing and able to undergo follow-up until death or the end of the study or study termination.

Exclusion Criteria

1. Have had any extrahepatic metastasis after being diagnosed with colorectal cancer.
2. Previous surgery, interventional ablation, hepatic arterial infusion (HAI), radiotherapy, or transarterial chemoembolization (TACE) for liver metastases.
3. Liver metastases intended for interventional ablation treatment only.
4. Presence of hepatic artery vascular variation identified by CTA examination, making HAI implantation unsuitable.
5. Severe arterial embolism or ascites.
6. Bleeding tendency or coagulation disorders.
7. Hypertensive crisis or hypertensive encephalopathy.
8. Severe uncontrollable systemic complications such as infection or diabetes.
9. Clinically significant cardiovascular diseases such as cerebrovascular accidents (in the last 6 months before enrollment), myocardial infarction (in the last 6 months before enrollment), uncontrolled hypertension despite appropriate drug treatment, unstable angina, congestive heart failure (NYHA 2-4), and arrhythmias requiring medication.
10. History of or physical examination indicating central nervous system diseases (such as primary brain tumors, uncontrollable epilepsy, any brain metastasis, or history of stroke).
11. Had any other malignant tumors in the past 5 years (excluding basal cell carcinoma and/or cervical carcinoma in situ after radical surgery).
12. Received any investigational drug treatment in the last 28 days before the study.
13. Any residual toxicity from previous chemotherapy (excluding alopecia), such as peripheral neuropathy ≥ NCI CTC v3.0 grade 2, makes the use of a treatment regimen containing oxaliplatin not considered.
14. Allergic to any drugs in the study.
15. Pregnant or lactating women who are not using or refuse to use effective non-hormonal contraception (intrauterine device, barrier contraception combined with spermicidal gel, or sterilization) in women of childbearing age (last menstrual period \< 2 years ago) or fertile men who cannot or do not wish to comply with the study protocol.
16. Presence of any other diseases, functional impairment due to metastatic lesions, or suspicious findings in the physical examination suggesting contraindications to the use of the investigational drug or placing the patient at a high risk of treatment-related complications.

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No